(Q54357790)

English

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Noel Jean Milpied

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

P Chevallier

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Pigneux

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

M Hunault

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

J Delaunay

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

F Perry

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

L Lode

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

S Richebourg

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

O Blanchet

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

N Vey

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

D Blaise

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

J-L Harousseau

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

M Mohty

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

22 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

467-469

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19847200%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

https://scigraph.springernature.com/pub.10.1038/leu.2009.214

0 references

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.214

21 January 2018

Interactive diagnostics in the indication to allogeneic SCT in AML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.214

21 January 2018

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.214

21 January 2018

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.214

21 January 2018

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.214

21 January 2018

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.214

21 January 2018

Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.214

7 January 2021

based on heuristic

inferred from DOI database lookup

NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.214

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54357790&oldid=1456801162"